Blue Trust Inc. Has $147,000 Holdings in Takeda Pharmaceutical Company Limited (NYSE:TAK)

Blue Trust Inc. increased its holdings in Takeda Pharmaceutical Company Limited (NYSE:TAK) by 107.3% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 11,359 shares of the company’s stock after buying an additional 5,879 shares during the period. Blue Trust Inc.’s holdings in Takeda Pharmaceutical were worth $147,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors also recently made changes to their positions in TAK. EverSource Wealth Advisors LLC grew its stake in shares of Takeda Pharmaceutical by 38.6% during the second quarter. EverSource Wealth Advisors LLC now owns 3,082 shares of the company’s stock worth $43,000 after buying an additional 859 shares during the last quarter. Headlands Technologies LLC bought a new stake in shares of Takeda Pharmaceutical during the second quarter worth $59,000. Hexagon Capital Partners LLC grew its stake in shares of Takeda Pharmaceutical by 34.3% in the third quarter. Hexagon Capital Partners LLC now owns 4,419 shares of the company’s stock worth $63,000 after purchasing an additional 1,129 shares during the last quarter. Ridgewood Investments LLC bought a new stake in shares of Takeda Pharmaceutical in the second quarter worth $89,000. Finally, GAMMA Investing LLC grew its stake in shares of Takeda Pharmaceutical by 136.1% in the third quarter. GAMMA Investing LLC now owns 6,295 shares of the company’s stock worth $90,000 after purchasing an additional 3,629 shares during the last quarter. 9.17% of the stock is currently owned by institutional investors and hedge funds.

Takeda Pharmaceutical Stock Performance

Shares of Takeda Pharmaceutical stock opened at $13.57 on Monday. The company has a quick ratio of 0.74, a current ratio of 1.26 and a debt-to-equity ratio of 0.65. Takeda Pharmaceutical Company Limited has a twelve month low of $12.57 and a twelve month high of $15.08. The stock has a market cap of $42.95 billion, a price-to-earnings ratio of 24.67, a P/E/G ratio of 0.27 and a beta of 0.54. The company’s fifty day moving average is $14.58 and its 200 day moving average is $13.78.

Takeda Pharmaceutical (NYSE:TAK) last released its earnings results on Wednesday, July 31st. The company reported $0.56 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.37 by $0.19. The business had revenue of $7.75 billion for the quarter. Takeda Pharmaceutical had a net margin of 6.02% and a return on equity of 10.11%. Sell-side analysts forecast that Takeda Pharmaceutical Company Limited will post 1.58 EPS for the current year.

About Takeda Pharmaceutical

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.